Drug Trial Radar · NCT01599806
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
Last checked: Nov 20, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
641
Actual
Start
Oct 2012
Primary completion
Aug 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Forest Laboratories
- First posted
- May 16, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to Doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis
Conditions
- Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI)Drug
Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
DoripenemDrug
500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)Drug
Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)Drug
Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis TestTime frame: At Day 5 visit. Day 5 visit is based on 24 hour periods from the first dose date and time.
- Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis TestTime frame: At TOC visit. TOC visit is 21 to 25 days from Randomization.
- Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis TestTime frame: At TOC visit. TOC visit is 21 to 25 days from Randomization.
Locations
57 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Detroit, Michigan
Research Site
St Louis, Missouri
Research Site
Indiana, Pennsylvania
Research Site
Rosario, Argentina
Research Site
Pazardzhik, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Veliko Tarnovo, Bulgaria
Research Site
Slavonski Brod, Croatia
Research Site
Zadar, Croatia
Research Site
Zagreb, Croatia
Research Site
Liberec, Czechia
Research Site
Prague, Czechia
Research Site
Hamburg, Germany
Research Site
Haifa, Israel
Research Site
Kfar Saba, Israel
Research Site
Modena, Italy
Research Site
Cuernavaca, MOR, Mexico
Research Site
Guadalajara, Mexico
Research Site
Zapopan, Mexico
Research Site
Arequipa, Peru
Research Site
Cercardo de Lima, Peru
Research Site
Cusco, Peru
Research Site
Lima, Peru
Research Site
Trujillo, Peru
Research Site
Bialystok, Poland
Research Site
Sochaczew, Poland
Research Site
Wroclaw, Poland
Research Site
Bucharest, Romania
Research Site
Oradea, Romania
Research Site
Sibiu, Romania
Research Site
Timișoara, Romania
Research Site
Moscow, Russia
Research Site
Nizhny Novgorod, Russia
Research Site
Novosibirsk, Russia
Research Site
Saint Petersburg, Russia
Research Site
Smolensk, Russia
Research Site
Tomsk, Russia
Research Site
Velikiy Novgorod, Russia
Research Site
Busan, South Korea
Research Site
Jeonnam, South Korea
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.